FPR2 agonist 3 (compound CMC23) is used to limit lactate dehydrogenase release in LPS-stimulated cultures and to reduce the levels of pro-inflammatory cytokines IL-1β and IL-6; it exerts its effects by downregulating phosphorylated STAT3 levels via the STAT3/SOCS3 signaling pathway.